These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 14744276)

  • 1. Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: a prospective registry.
    Qureshi AI; Siddiqui AM; Hanel RA; Xavier AR; Kim SH; Kirmani JF; Boulos AS; Hopkins LN
    Neurosurgery; 2004 Feb; 54(2):307-16; discussion 316-7. PubMed ID: 14744276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement.
    Qureshi AI; Ali Z; Suri MF; Kim SH; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN
    Neurosurgery; 2001 May; 48(5):998-1004; discussion 1004-5. PubMed ID: 11334301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.
    Qureshi AI; Suri MF; Khan J; Fessler RD; Guterman LR; Hopkins LN
    Neurosurgery; 2000 Jun; 46(6):1316-24; discussion 1324-5. PubMed ID: 10834637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab.
    Qureshi AI; Suri MF; Ali Z; Kim SH; Lanzino G; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN
    Neurosurgery; 2002 Mar; 50(3):466-73; discussion 473-5. PubMed ID: 11841713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
    Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
    N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions.
    Fischell TA; Attia T; Rane S; Salman W
    J Invasive Cardiol; 2006 Oct; 18(10):487-91. PubMed ID: 17042093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and feasibility of intraarterial eptifibatide as a revascularization tool in acute ischemic stroke.
    Memon MZ; Natarajan SK; Sharma J; Mathews MS; Snyder KV; Siddiqui AH; Hopkins LN; Levy EI
    J Neurosurg; 2011 Apr; 114(4):1008-13. PubMed ID: 20868216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Goa KL; Noble S
    Drugs; 1999 Mar; 57(3):439-62. PubMed ID: 10193692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).
    Le May MR; Wells GA; Glover CA; So DY; Froeschl M; Marquis JF; O'Brien ER; Turek M; Thomas A; Kass M; Jadhav S; Labinaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):330-8. PubMed ID: 20031736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
    Fung AY; Saw J; Starovoytov A; Densem C; Jokhi P; Walsh SJ; Fox RS; Humphries KH; Aymong E; Ricci DR; Webb JG; Hamburger JN; Carere RG; Buller CE
    J Am Coll Cardiol; 2009 Mar; 53(10):837-45. PubMed ID: 19264239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eptifibatide bridging therapy for staged carotid artery stenting and cardiac surgery: Safety and feasibility.
    Caton MT; Narsinh KH; Baker A; Amans MR; Hetts SW; Rapp JH; Ianuzzi JC; Tseng E; Gasper WJ; Cooke DL
    Vascular; 2024 Apr; 32(2):433-439. PubMed ID: 35341420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eptifibatide use following emergent carotid stenting in acute anterior circulation ischemic stroke with tandem occlusion.
    Osteraas ND; Crowley RW; Panos N; Dafer RM
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105021. PubMed ID: 32807436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
    Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.
    Wholey MH; Wholey MH; Eles G; Toursakissian B; Bailey S; Jarmolowski C; Tan WA
    J Endovasc Ther; 2003 Feb; 10(1):33-41. PubMed ID: 12751927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents.
    Ben Morrison T; Horst BM; Brown MJ; Bell MR; Daniels PR
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):575-82. PubMed ID: 22448399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.
    Tcheng JE; Harrington RA; Kottke-Marchant K; Kleiman NS; Ellis SG; Kereiakes DJ; Mick MJ; Navetta FI; Smith JE; Worley SJ
    Circulation; 1995 Apr; 91(8):2151-7. PubMed ID: 7697843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study.
    Kaul U; Gupta RK; Haridas KK; Ramesh SS; Sethi KK; Singh B; Agarwal R; Yadave RD; Ghose T; Sapra RR; Bajaj R; Shahi M; Bhagwat A; Kumar P; Mathews OP; Soni PK;
    Catheter Cardiovasc Interv; 2002 Dec; 57(4):497-503. PubMed ID: 12455085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.